Remission of high‐grade B‐cell lymphoma in a pediatric patient following <i>Helicobacter pylori</i> eradication

Furaikh, Samia Saud Al

doi:10.1111/j.1442-200x.2010.03142.x

Cited by 10 publications

(6 citation statements)

References 10 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…34,37 Considering these facts, histological improvement may be expected after H. pylori is eradicated in the infected children with chronic gastritis. Comments There is only one review 8 and three case reports [38][39][40] about H. pylori eradication therapies for MALT lymphoma in children. In a 14-year-old American girl with H. pylori-positive gastritis and low-grade MALT lymphoma, the lymphoproliferative lesion was improved with the eradication therapy and no recurrence of the lesion was detected at 7 year follow up.…”

Section: [Clinical Question 3]mentioning

confidence: 99%

“…39 In an 8-year-old Saudi Arabian boy with IDA and H. pylori-positive gastritis, high-grade B cell lymphoma was detected 3 months after completion of eradication therapy but the lymphoma lesion completely disappeared with continuing eradication therapy. 40 We recommend consideration of eradication therapy in children with gastric MALT lymphoma, when H. pylori infection is confirmed. Comments There are no systematic reviews or randomized controlled trials with regard to this clinical question.…”

Section: [Clinical Question 3]mentioning

confidence: 99%

“…There is only one review 8 and three case reports 38–40 about H. pylori eradication therapies for MALT lymphoma in children. In a 14‐year‐old American girl with H. pylori ‐positive gastritis and low‐grade MALT lymphoma, the lymphoproliferative lesion was improved with the eradication therapy and no recurrence of the lesion was detected at 7 year follow up 38 .…”

Section: H Pylori‐associated Diseasesmentioning

confidence: 99%

See 2 more Smart Citations

The updated JSPGHAN guidelines for the management ofHelicobacter pyloriinfection in childhood

Kato

Shimizu

Toyoda³

et al. 2020

Pediatrics International

View full text Add to dashboard Cite

The Japan Pediatric Helicobacter pylori Study Group published the first guidelines on childhood H. pylori infection in 1997. They were later revised by the Japanese Society for Pediatric Gastroenterology, Hepatology and Nutrition (JSPGHAN). The H. pylori eradication rates, when employing triple therapy with amoxicillin and clarithromycin, currently recommended as the first-line therapy of H. pylori infection in Japan, have substantially decreased, creating an important clinical problem worldwide. In Japanese adults, the "test-and-treat" strategy for H. pylori infection is under consideration as an approach for gastric cancer prevention. However, the combined North American and European pediatric guidelines have rejected such a strategy for asymptomatic children. As risk for gastric cancer development is high in Japan, determining whether the "test-and-treat" strategy can be recommended in children has become an urgent matter. Accordingly, the JSPGHAN has produced a second revision of the H. pylori guidelines, which includes discussion about the issues mentioned above. They consist of 19 clinical questions and 34 statements. An H. pylori culture from gastric biopsies is recommended, not only as a diagnostic test for active infection but for antimicrobial susceptibility testing to optimize eradication therapy. Based upon antimicrobial susceptibility testing of H. pylori strains (especially involving clarithromycin), an eradication regimen including use of the antibiotics to which H. pylori is susceptible is recommended as the first-line therapy against H. pylori-associated diseases. The guidelines recommend against a "test-and-treat" strategy for H. pylori infection for asymptomatic children to protect against the development of gastric cancer because there has been no evidence supporting this strategy.

show abstract

Section: [Clinical Question 3]mentioning

confidence: 99%

Section: [Clinical Question 3]mentioning

confidence: 99%

Section: H Pylori‐associated Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

The updated JSPGHAN guidelines for the management ofHelicobacter pyloriinfection in childhood

Kato

Shimizu

Toyoda³

et al. 2020

Pediatrics International

View full text Add to dashboard Cite

show abstract

“…If left untreated, it can cause chronic gastritis, peptic ulcer, gastric adenocarcinomas [7], and mucosa-associated lymphoid tissue (MALT) lymphomas [8]. Fortunately, H. pylori associated gastric cancer has not been reported in pediatric age group, but MALT lymphomas have been described in a few H. pylori infected children [9–11]. In an adult study, early eradication of H. pylori has been associated with a sixfold reduction in the recurrence of peptic ulcers as well as a twofold to threefold reduction in the risk of gastric carcinoma [12].…”

Section: Introductionmentioning

confidence: 99%

The Effects of Synbiotic “Bifidobacterium lactisB94 plus Inulin” Addition on Standard Triple Therapy ofHelicobacter pyloriEradication in Children

Üstündağ

ALTUNTAŞ

Soysal

et al. 2017

Canadian Journal of Gastroenterology and Hepatology

View full text Add to dashboard Cite

Aim The aim of this study is to evaluate the effects of the synbiotic Bifidobacterium lactis B94 plus inulin addition to the standard triple therapy on Helicobacter pylori (H. pylori) infection eradication rates. Methods Children aged 6–16 years who had biopsy proven H. pylori infection were randomly classified into two groups. The first group received the standard triple therapy consisting of amoxicillin + clarithromycin + omeprazole. The second group was treated with the standard triple therapy and Bifidobacterium lactis B94 (5 × 109 CFU/dose) plus inulin (900 mg) for 14 days, concurrently. Eradication was determined by 14C-urea breath test 4–6 weeks after therapy discontinuation. Results From a total of 69 H. pylori infected children (F/M = 36/33; mean ± SD = 11.2 ± 3.0 years), eradication was achieved in 20/34 participants in the standard therapy group and 27/35 participants in the synbiotic group. The eradication rates were not significantly different between the standard therapy and the synbiotic groups [intent-to-treat, 58.8% and 77.1%, resp., p = 0.16; per-protocol, 64.5% and 81.8%, resp., p = 0.19]. There was no difference between the groups in terms of symptom relief (p = 0.193). The reported side effects were ignorable. Conclusion Considering the eradication rates, synbiotic addition to therapy showed no superiority over the standard triple therapy conducted alone. This trial is registered with NCT03165253.

show abstract

“…However, a few cases of regression of these lymphomas after the cure of H. pylori infection have been described 80 . Thus, recent studies have shown that H. pylori eradication results in durable histological complete remission in approximately 50% of patients with large B‐cell lymphomas of the stomach with concomitant MALT areas 81–90 . As an example, Chen et al., 89 reported in a prospective study the disappearance of primary gastric large B‐cell lymphoma at gastroscopy examination in 14 of 22 patients (64%) after H. pylori eradication therapy.…”

Section: H Pylori Eradication Has No Role In the Treatment Of High‐gmentioning

confidence: 99%

Review article: common misconceptions in the management of Helicobacter pylori-associated gastric MALT-lymphoma

Gisbert

2011

Alimentary Pharmacology &Amp; Therapeutics

View full text Add to dashboard Cite

show abstract

Remission of high‐grade B‐cell lymphoma in a pediatric patient following Helicobacter pylori eradication

Cited by 10 publications

References 10 publications

The updated JSPGHAN guidelines for the management ofHelicobacter pyloriinfection in childhood

The updated JSPGHAN guidelines for the management ofHelicobacter pyloriinfection in childhood

The Effects of Synbiotic “Bifidobacterium lactisB94 plus Inulin” Addition on Standard Triple Therapy ofHelicobacter pyloriEradication in Children

Review article: common misconceptions in the management of Helicobacter pylori-associated gastric MALT-lymphoma

Contact Info

Product

Resources

About